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Although the nature of the noxious signal and the ana-
tomical target in alopecia areata (AA) are still un-
known, it has been assumed that CD4+ T lymphocytes 
surrounding and infiltrating the hair bulb might 
trigger the hair loss. As these T lymphocytes do not 
promote cytotoxic activity we hypothesize that AA is 
triggered by cytokines. Topical immunotherapy with 
diphenylcyclopropenone (DCP) is at present the 
most effective approach. If it is true that AA results 
from a distinct cytokine pattern, we can hypothesize 
that the beneficial effect of DCP should be mediated 
by locally secreted cytokines during the contact al-
lergy. Using semiquantitative reverse transcription-
polymerase chain reaction with RNA extracted from 
scalp biopsies from patients with AA before and after 
successful treatment with DCP, and from healthy con-
trols we detected aT-cell response with increased 
steady state nill.NA levels for interferon (IFN)-y, inter-
leukin (IL)-lP, and IL-2 in untreated AA of the totalis 
A lopecia areata (AA) is a common disease of the hair follicle affecting about 1-2% of the total of new patients attending dermatology clinics. The unpre-dictable course of the disease and the lack of a specific treatment have profound effects on the quality of life 
of aff~cted individuals. The events in AA that induce premature 
telogen or dystrophic anagen growth pattern are not understood. In 
the past, immunologic studies have provided evidence that CD4+ T 
lymphocytes surrounding and infiltrating the affected hair bulbs 
might trigger the hair loss [1,2]. Although the nature of the noxious 
signal and the anatomical target are still unknown, it has been as-
sumed that an autoimmune process is involved [3]. 
Unequivocal evidence for the existence of antifollicle autoim-
mune reactivity is still lacking. and other immunologic findings 
have likewise attracted much attention. In this regard increased 
levels of soluble interleukin (IL)-2 receptors [4] and increased ex-
pression of adhesion molecules (ICAM-l , ELAM) [5,6] and HLA-
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type. After DCP treatment, the IFN-y expression was 
reduced but still above the constitutive level found in 
controls, whereas mRNA expression ofIL-2, IL-8, IL-
10, and tumor necrosis factor-a was increased. Our 
results point towards cytokines involved in the patho-
genesis in AA. AT H 1 type cytokine pattern is present in 
untreated AA, and this is modified by cytokines se-
creted during DCP treatment. IL-10 has recently been 
described as an immunomodulator of the THl response 
and, therefore, we hypothesize that basal keratinocytes 
or lesional T cells secrete bioactive IL-10 after DCP 
application, resulting in an inhibitory effect on le-
sional T lymphocytes. This hypothesis would explain 
the effectiveness of DCP and implies the theoretical 
possibility of a response to topical or intralesional ap-
plication of recombinant IL-10. Key words: alopecia ar-
eatajdiphenylcyclopropenone. J Invest Dermatol 103:530-
533, 1994 
DR/HLA-A13C molecules on affected hair follicles and endothelial 
cells [7 - 9] have been reported. So far, however, no comprehensive 
pathophysiologic explanation for these findings is available. 
In AA the hair follicles are not destroyed but rather "switched 
off" in stage IV [10] anagen although T lymphocytes invade the 
hair follicles and apparently interact with the matrix cells. Such 
interaction may occur either by direct cell-to-cell contact and cyto-
toxicity, or indirectly by lymphokines that might affect the differ-
entiation and growth of follicular epithelial cells. As the T lympho-
cytes obviously do not promote cytotoxic activity we hypothesize 
that AA is triggered by soluble mediators. The presence of such 
mediators (e.g., interferon [IFN]-y, tumor necrosis factor [TNF]-a) 
would explain increased adhesion molecule expression on affected 
hair follicles and the non-destructive nature of the disease. 
At present, topical immunotherapy with a potent contact allergen 
such as diphenylcyclopropenone (DCP) appears to be superior to all 
other modes of treatment [11-14]. Why an allergic contact derma-
titis should reverse the pathogenic process and induce hair regrowth 
is still unknown. According to present knowledge, the initiation 
and maintenance of an allergic contact dermatitis involves a cascade 
of events in which cytokines are supposed to playa crucial role [15] . 
In particular, IL-1P, TNF-a, IFN-y, IL-2, IL-8, and IL-IO have 
been demonstrated to be preferentially expressed in allergic contact 
dermatitis [16-19]. 
If it is true that AA is the result of a distinct cytokine pattern, we 
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Table I. List of Primer Pairs Used for Cytokine mRNA 
Amplification, with Data Regarding the Annealing 
Temperature (TmOC), the Size of the PCR Products, and 
the PCR Cycles Within a Linear Range for Amplification 
Primer Tm(oq bp Cycles 
fJ-actin 60 838 22 
IFN-y 63 427 36 
IL-lfJ 60 802 28 
IL-2 63 458 38 
IL-4 60 465 40 
IL-6 60 628 33 
IL-8 65 289 31 
IL-I0 65 432 33 
TNF-a 60 444 28 
can infer that the beneficial effect of contact allergy is mediated by 
locally secreted cytokines neutralizing this noxious pattern. To find 
an answer to this hypothesis, we performed semiquantitative 
polymerase chain reaction (PCR) for a panel of cytokines in scalp 
biopsies obtained from healthy controls and patients with AA be-
fore and after successful treatment with DCP. A differential expres-
sion of distinct cytokine patterns, implying the possibility of a novel 
therapeutic approach, will be described. 
MATERIALS AND METHODS 
Patients With informed consent, excisional scalp biopsies were taken. As 
controls, scalp biopsies obtained from five patients (31 -65 years of age, 
mean 41 years) undergoing elective neurosurgery were used. They had no 
inflammatory skin disease, no systemic disease, and no immunosuppressive 
therapy. Biopsies were taken from 12 patients (25 - 55 years of age, mean 36 
years) with alopecia areala of the totalis type. After skin biopsy, sensitization 
was induced by painting an area of25 cm2 of the patient scalp with 2% DCP. 
Subsequently, elicitation and maintenance of a contract dermatitis were 
accomplished by weekly applications with DCP concentrations varying 
from 1 % to 0.0000001 %. When a response in the form of hair regrowth 
after unilateral treatment was noted (in 10 patients, approximately 8-18 
weeks after the initiation of the contact dermatitis), additional skin biopsies 
were taken 24-36 h after the last DCP application. 
Chemicals Guanidinium thiocyanate, Tris-borate, glycerol , bromo-
phenol bluc, Tris-HCI, and NaCINa2H2 ethylencdiaminetetraacetic acid 
(EDT A} were purchased from Sigma (Dcisenhofcn, Germany), and phenol, 
isopropanol, and chloroform from Merck (Darmstadt, Gcrmany). The taq 
polymerasc and the kit for reverse transcription (RT kit) camc from Phar-
macia (Uppsala, Sweden). Ethidium bromide and the DNA-VIII molecular 
weight marker came from Boehringer Mannheim (Manuheim, Germany). 
Primers for PCR amplification of fJ-actin, IFN-y, IL-l/l, IL-2, IL-4, IL-6, 
IL-8, and TNF-a were bought from C lontech (Palo Alto, CAl. Primers for 
IL-I0 were purchased from Stratagene (Heidelberg, Gcrmany). These 
primer pairs arc all intron-spanning to avoid amplification of contaminating 
genomic DNA. 
Extraction of Total RNA From Excisional Scalp Biopsies Total 
RNA from scalp skin was isolated according to Chomczynski and Sacchi 
(20). Twenty milligrams wet weight scalp skin was frozen in liquid nitro-
gen, minced, resuspended in guanidinium thiocyanate followed by addition 
of acidified phcnol/ch loroform. After centrifugation, the RNA was precipi-
tated from the aqueous phase with isopropanol. Individual RNA samples 
from different paticnts were equalized with regard to their RNA concentra-
tion by ultraviolet (UV) spectroscopy. The RNA was dissolved in RNasc-
free sterile water. Approximately 10,ug total RNA was isolatcd from each 
preparation. 
PCR Analysis of Cytokine mRNA and p-Actin mRNA About 1 ,ug 
of total RN A from biopsies was reverse transcribed with random hexamer 
primers and moloney mnrine reverse transcriptase tumor virus. Each primer 
pair was tested on total RNA and subsequent PCR amplification without 
prior reverse transcription. No PCR products werc obtained in controls. For 
each primer pair a three-temperature-stcp PCR cycle program waS carried 
out (2 min annealing, 2 min extension at 72°C, and 1 min denaturation at 
94 0 C; Table I). This PCR setup was optimizcd to obtain only onc PCR 
product of the expected length (Table I) . Standard curves for the amount of 
RNA and cycle numbers were establishcd as described [21J. The specificity 
of each PCR product was demonstrated by comparison of expected PCR 
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product length with the actual Icngth of the amplified DNA visualized by 
gel electrophoresis, comparison with the given positive controls provided by 
CIon tech, and by restriction analysis of the amplified DNA fragments. 
Semiquantitative analysis of rhe PCR amplification products was achieved 
by high-performance liquid chromatography (HPLC) [21]. The specific 
PCR products were recognized by their elution time in comparison to a 
DNA standard. Before calculation of rhe cytokine mRNA expressions, the 
probes were equalized for /l-actin mRNA as an internal standard. This was 
achieved by coall1pl ification of the /l-actin Il1RNA to each cytokinc mRNA 
followed by HPLC analysis. The mean peak area for each cytokine in 10 
patients/five controls was calculated. Constitutive cytokine expression 
levels in thc controls were set to zero. 
HPLC Operating Conditions As shown previously [21 ], semiquantita-
tive analysis of PCR products by HPLC allows a precise calculation of the 
amount of PCR-amplified transcripts. Opcrating conditions and buffers 
were as described [21]. 
Gel Electrophoresis For documcntation of the different cytokine PCR 
products, thc resulting PCR products were precipitated with ice-cold eth-
anol and ccntrifuged for 20 min . The remaining DNA was dissolved in20 ,ul 
Tris-borate-EDTA buffer and loaded in an alkaline 1 % agarose gel [22]. The 
gels were stained with 0.1 ,ug/1l11 ethidium bromide in TBE bufFer and 
visualized under UV light (data not shown). 
RESULTS 
The PCR primers for the different cytokines were shown to specifi-
cally amplify the expected cytokine mRNA. All primer pairs used 
resulted in one PCR product of the expected length and expected 
fragments after restriction analysis. Using semiquantitative PCR 
technology by HPLC analysis of PCR products, a reliable quantifi-
cation through integration of the relevant peak area is possible; a 
typical chromatogram of amplified /l-actin cDNA is shown in Fig 
1. The peak areas of the corresponding PCR products are propor-
tional to the amount of DNA loaded onto the analytical column, 
allowing precise quantitation. In Fig 1, a typical HPLC run for an 
838-base pair (bp) PCR product for /l-actin is shown. The PCR 
amplification profile of each primer pair was estimated empirically 
by analysis of increasing PCR with equal amounts of reverse tran-
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Fignre 1. Example of semiquantitative HPLC analysis ofRT-PCR 
product. Approximately 1 ,ug of total RNA was subjected to RT-PCR/ 
HPLC for /l-actin mRNA in scalp biopsies. The chromatogram shows a 
typical HPLC run of the completed PCR. Besides dNTPs and primers, a 
single peak corresponding to the 838-bp reverse-transcribed and amplified 
/l-actin mRNA is found. Quantification of the PC R products is done 
through peak area integration. The peak areas are proportional to the 
amount of DNA loaded onto the analytical column. As the elution time 
depends on the overall charges of DNA molecules, PCR products of difFer-
ent length can be differentiated. 
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scribed RNA. PCR cycles ultimately chosen for the PCR were in 
the linear range for each primer pair (Table I). 
Using our experimental approach we detected increased steady 
state mRNA levels for IL-1P, IL-2, and IFN-y in comparison to the 
constitutive mRNA expression of these cytokines in intact scalp 
from healthy donors (Fig 2) . Transcripts for IL-4 were found nei-
ther in patients nor in healthy donors. Furthermore, transcripts for 
IL-6, IL-8, IL-10, and TNF-a mRNA were present in all samples, 
but the expression pattern in scalp specimens from patients with AA 
was nearly similar to those detected in scalp biopsies from healthy 
donors. As the effectivity for PCR amplification is not necessarily 
equal for different primer pairs, a quantitative comparison of differ-
ent primers is not possible. Thus, we cannot say which cytokine is 
maximally expressed in AA. 
Subsequently, one-half of the scalp from patients with AA was 
painted with DCP, as described in Materials and Methods. After uni-
lateral hair regrowth was noted, additional scalp biopsies were taken 
24 - 36 h after DCP application. The experimental design and se-
miquantitative analysis of the different cytokines was performed in 
the same way as described above. Compared to control scalp, in 
successfully DCP-treated AA we found increased mRNA steady 
state levels for IL-2, IL-8, IL-10, and TNF-a (Fig 3). Again no 
transcripts for IL-4 were found, whereas IL-6 mRNA expression 
was low. IFN-y and IL-1P transcripts were increased when com-
pared to controls, but compared to untreated AA, the overall ex-
pression levels were 60% and 15% reduced for IFN-y and IL-1P, 
respectively (compare Figs 2 and 3). 
DISCUSSION 
To explain the pathogenesis of AA, it has been assumed that T 
lymphocytes surrounding and infiltrating the hai r bulb trigger an 
autoimmune process, directed against some so far unidentified 
growth-controlling factor(s) or their receptor(s) [23]. As affected 
hair roots are rather "switched off" than destroyed, the inhibitory 
effect on the hair cycle in AA can be best explained by soluble 
mediators released from lesional T lymphocytes. 
Here we provide experimental evidence that cytokines partici-
pate in the pathogenesis of AA. We detected increased lesional 
levels of IFN-y, IL-2, and IL-1P transcripts in scalp biopsies from 
patients with untreated AA, corresponding to a cytokine pattern of 
the T H 1 T -helper type. This pattern has been shown to mediate 
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Figure 2. Cytokine mRNA expression in alopecia areata as compared 
to healthy controls. One microgram total RNA aliquots from patients and 
controls were reverse transcribed and subjected to PCR amplification for the 
indicated mediators. The expression of p-actin mRNA was always coampli-
fied to serve as an internal standard. Expression levels for the various cyto-
kines in the different skin samples were calculated by equalizing the samples 
to their p-actin mRNA expression, and by setting the constitutive cytokine 
mRNA expression in healthy control scalp to zero. Presented data are mean 
values (error bars, ± SD) of the expression levels from 10 patients and five 
controls. Transcripts for IL-4 were not detected. 
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Figure 3. Cytokine mRNA expression in alopecia areata after treat-
ment with DCP. The experimental design was the same as described for 
Fig 2. Biopsies were taken after unilateral hair regrowth was noted after 
DCP treatment. Presented data are mean values (error bars, ± SD) of the 
expression levels from 10 patients and five controls. 
delayed-type hypersensitivity responses [24]. Following this line of 
thought IL-2 would promote activation and clonal expansion of 
lesional T lymphocytes . Furthermore, our findings offer an expla-
nation for the aberrant expression of molecules such as ICAM-l and 
HLA-DR on affected hair follicles in AA. Our results confirm 
previous studies demonstrating the presence of IFN-y and IL-2 
within the peribulbar T-cell infiltrate [25]. 
Topical immunotherapy is effective in AA, but many questions 
regarding this treatment are still unanswered. The fact that similar 
results can be obtained with contact allergens of different structure 
indicates that the therapeutic effect is not due to a specific pharma-
cologic mechanism but to an immune response common to different 
allergens [26] . An initial step to provide evidence that the therapeu-
tic effect may be ascribed to topical "immunomodulation" was 
achieved by studies in which the ratio of peribulbar CD4+ /CD8+ T 
cells was shown to decrease from 4: 1 to nearly 1 : 1 [27]. Moreover, 
the aberrant expression of HLA-ABC and HLA-DR molecules on 
affected hair follicles was shown to be down-modulated after treat-
ment with DCP [28], compatible with the concept of antigenic 
competition [29]. 
As we detected increased mRNA-levels for IL-2, IL-8, IL-I0, and 
TNF-a in DCP-treated AA, we suggest that the beneficial effect of 
contact allergens are due to immunomodulation by pro-inflamma-
tory cytokines released by keratinocytes or lesional T cells. Our 
findin gs are supported by several reports concerning the mediators 
present during initiation and amplification of a contact allergy, 
demonstrating a preferential expression ofTNF-a, IFN-y, IL-1P, 
IL-8, and IL-10 in lesional skin [1 6- 19]' 
At present we cannot define the mediator(s) responsible for the 
therapeutic response. However, IFN-y has been shown to inhibit 
IL-4 -mediated T H2-type responses [30], whereas IL-4 was shown 
to reduce T H 1-type responses [31]. More recently IL-10 was charac-
terized by its ability to inhibit T H 1 cytokine production [32]. Several 
lines of evidence, however, show a more pleiotropic function of 
IL-IO as a modulator of immune responses [33,34]. Several docu-
mented immunologic effects after DCP treatment of AA may be 
ascribed to the presence of IL-1 ° in basal keratinocytes [35] and in 
their vicinity. W e observed a reduced expression level of IFN-y in 
lesional AA scalp after treatment with DCP. We do not know 
whether this is of clinical significance, but IL-I0 has been shown to 
inhibit IFN-y-mediated responses [36] and this may explain the 
decreased expression of molecules such as ICAM-1 and HLA-DR in 
DCP-treated AA, although we cannot exclude an immunomodu-
lating action of IL-8 and TNF-a as well. At present we cannot say 
what happens in unsuccessfully DCP-treated AA but it has been 
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demonstrated [5] that iCAM-l expression is still present in lesional 
hair bulbs; this might reflect a different immune response after DCP 
treatment in those patients. 
In conclusion, we provide evidence that a cytokine pattern of the 
T H 1 type participates in the pathogenesis of AA. From the detection 
of IL-I0 transcripts in DCP-treated AA we infer that IL-IO inhibits 
the T H 1 response. We cannot say whether this suppressive effect is 
directed against lesional T cells or against antigen-presenting cells 
(APC), but possibly IL-IO-dependent inhibition of APC function 
is a crucial mechanism [37] . Theoretically, application of IL-10 
should provide a therapeutic approach for AA. As a potent immune 
response modifier ofT H 1 T -cells, recombinant IL-l 0 might be ben-
eficial when applied topically. If so, this approach would be more 
specific than application of a potent contact allergen. 
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